Last reviewed · How we verify
TERCONAZOLE
At a glance
| Generic name | TERCONAZOLE |
|---|---|
| Drug class | Azole Antifungal [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
Common side effects
- Headache
- Body pain
- Fever
- Vulvovaginal burning
- Vulvovaginal itching
- Vulvovaginal irritation
- Chills
Serious adverse events
- Anaphylaxis
- Toxic Epidermal Necrolysis
- Bronchospasm
- Hypersensitivity
- Face Edema
- Influenza-Like Illness
Key clinical trials
- Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis (NA)
- Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis (PHASE4)
- Multi-Center Study of New Medications to Treat Vaginal Infections (PHASE3)
- Multi-Center Study of New Medications to Treat Vaginal Infections (PHASE3)
- Multi-Center Study of New Medications to Treat Vaginal Infections (PHASE3)
- Comparison of Boric Acid vs. Terconazole in Treatment of RVVC (NA)
- Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis (PHASE3)
- In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TERCONAZOLE CI brief — competitive landscape report
- TERCONAZOLE updates RSS · CI watch RSS